FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042663838> ?p ?o ?g. }

• W2042663838 endingPage "812" @default.
• W2042663838 startingPage "799" @default.
• W2042663838 abstract "It is no a secret that we are confronted by an alarmingly increasing number of patients with progressive renal disease. There is ample evidence for the notion that angiotensin II (Ang II) is a major culprit in progression. The vasopeptide Ang II turned out to have also multiple nonhemodynamic pathophysiologic actions on the kidney, including proinflammatory and profibrogenic effects. Diverse complex Ang II generating systems have been identified, including specifically local tissue-specific renin-angiotensin systems (RAS). For example, proximal tubular cells have all components required for a functional RAS capable of synthesizing Ang II. On the other hand, Ang II is not the only effector of the RAS and other peptides generated by the RAS influence renal function and structure as well. Moreover, the discoveries that Ang II can be generated by enzymes other than angiotensin-converting enzyme (ACE) and that Ang II and other RAS derived peptides bind to various receptors with different functional consequences have further added to the complexity of this system. Several major clinical trials have clearly shown that ACE inhibitor treatment slows the progression of renal diseases, including in diabetic nephropathy. Well-controlled studies demonstrated that this effect is in part independent of blood pressure control. More recently, with Ang II type 1 receptor (AT(1)) receptor antagonists a similarly protective effect on renal function was seen in patients with type 2 diabetes. Neither ACE inhibitor treatment nor AT(1) receptor blockade completely abrogate progression of renal disease. A recently introduced novel therapeutic approach is combination treatment comprising both ACE inhibitor and AT(1) receptor antagonists. The rationale for this approach is based on several considerations. Small-scale clinical studies, mainly of crossover design, documented that combination therapy is more potent in reducing proteinuria in patients with different chronic renal diseases. Blood pressure as an important confounder was, however, significantly lower in the majority of this studies in the combination treatment arms compared to the respective monotherapies. In a recent prospective study Japanese authors avoided this confounder and demonstrated that combination therapy reduced hard end-points (end stage renal failure or doubling of serum creatinine concentration) by 50% compared to the respective monotherapies. This effect could not be explained by a more pronounced reduction of blood pressure in the combination therapy group. Although these results are encouraging, administration of combination therapy should be reserved currently to special high risk groups. Further studies are necessary to confirm these promising results. It is possible that combination therapy may increase the risk of hyperkalemia, particularly when with coadministered with medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) or spironolactone. In our opinion patients with proteinuria >1 g/day despite optimal blood pressure control under RAS-blocking monotherapy are a high-risk group which will presumably benefit from combination therapy." @default.
• W2042663838 created "2016-06-24" @default.
• W2042663838 creator A5022731076 @default.
• W2042663838 creator A5070005567 @default.
• W2042663838 date "2005-03-01" @default.
• W2042663838 modified "2023-09-30" @default.
• W2042663838 title "Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications" @default.
• W2042663838 cites W130961871 @default.
• W2042663838 cites W1548675089 @default.
• W2042663838 cites W1931208941 @default.
• W2042663838 cites W1963095561 @default.
• W2042663838 cites W1974587800 @default.
• W2042663838 cites W1980399901 @default.
• W2042663838 cites W1981841934 @default.
• W2042663838 cites W1982154515 @default.
• W2042663838 cites W1985005344 @default.
• W2042663838 cites W1992750772 @default.
• W2042663838 cites W1992995831 @default.
• W2042663838 cites W1993417379 @default.
• W2042663838 cites W1997455782 @default.
• W2042663838 cites W1997932090 @default.
• W2042663838 cites W1998038903 @default.
• W2042663838 cites W2001253024 @default.
• W2042663838 cites W2002110085 @default.
• W2042663838 cites W2002616791 @default.
• W2042663838 cites W2003081992 @default.
• W2042663838 cites W2004295653 @default.
• W2042663838 cites W2004840558 @default.
• W2042663838 cites W2006999079 @default.
• W2042663838 cites W2007000110 @default.
• W2042663838 cites W2009826896 @default.
• W2042663838 cites W2013216543 @default.
• W2042663838 cites W2013926666 @default.
• W2042663838 cites W2015471827 @default.
• W2042663838 cites W2016698332 @default.
• W2042663838 cites W2019019126 @default.
• W2042663838 cites W2019639026 @default.
• W2042663838 cites W2022846000 @default.
• W2042663838 cites W2025672718 @default.
• W2042663838 cites W2027550108 @default.
• W2042663838 cites W2031534703 @default.
• W2042663838 cites W2034792442 @default.
• W2042663838 cites W2044049836 @default.
• W2042663838 cites W2044773944 @default.
• W2042663838 cites W2047056322 @default.
• W2042663838 cites W2047390341 @default.
• W2042663838 cites W2052679130 @default.
• W2042663838 cites W2056976690 @default.
• W2042663838 cites W2060204625 @default.
• W2042663838 cites W2060993823 @default.
• W2042663838 cites W2061173243 @default.
• W2042663838 cites W2062409427 @default.
• W2042663838 cites W2064732202 @default.
• W2042663838 cites W2066538838 @default.
• W2042663838 cites W2067679874 @default.
• W2042663838 cites W2075391935 @default.
• W2042663838 cites W2079306975 @default.
• W2042663838 cites W2083008696 @default.
• W2042663838 cites W2084138782 @default.
• W2042663838 cites W2084343172 @default.
• W2042663838 cites W2085237161 @default.
• W2042663838 cites W2086444493 @default.
• W2042663838 cites W2097288698 @default.
• W2042663838 cites W2100546222 @default.
• W2042663838 cites W2103462106 @default.
• W2042663838 cites W2106727620 @default.
• W2042663838 cites W2106952837 @default.
• W2042663838 cites W2107623737 @default.
• W2042663838 cites W2111780029 @default.
• W2042663838 cites W2111965899 @default.
• W2042663838 cites W2115932546 @default.
• W2042663838 cites W2115940615 @default.
• W2042663838 cites W2117539329 @default.
• W2042663838 cites W2118286022 @default.
• W2042663838 cites W2122598696 @default.
• W2042663838 cites W2125316810 @default.
• W2042663838 cites W2125429703 @default.
• W2042663838 cites W2126175185 @default.
• W2042663838 cites W2129537648 @default.
• W2042663838 cites W2133217116 @default.
• W2042663838 cites W2135285685 @default.
• W2042663838 cites W2137946319 @default.
• W2042663838 cites W2138670606 @default.
• W2042663838 cites W2139124675 @default.
• W2042663838 cites W2140172772 @default.
• W2042663838 cites W2140745413 @default.
• W2042663838 cites W2141120643 @default.
• W2042663838 cites W2141807410 @default.
• W2042663838 cites W2142459107 @default.
• W2042663838 cites W2142563692 @default.
• W2042663838 cites W2142967092 @default.
• W2042663838 cites W2143144750 @default.
• W2042663838 cites W2143515869 @default.
• W2042663838 cites W2149073112 @default.
• W2042663838 cites W2155498062 @default.
• W2042663838 cites W2157734027 @default.
• W2042663838 cites W2160541810 @default.
• W2042663838 cites W2160934553 @default.

• next